

- Jun 29, 2021
NCT04770402: Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients


- Jun 29, 2021
NCT04934475: Phase 3 - IFM 2020-02 Minimal Residual Disease Adapted Strategy (MIDAS) KRD-Isatuximab


- Jun 27, 2021
NCT04942067: Phase 1/2: APG-2575 in Combination With Novel Therapeutic Regimens in RRMM Myeloma


- Jun 26, 2021
THE MMRF - Multiple Myeloma Immunotherapy


- Jun 25, 2021
NCT04775550: Phase 2: DARA RVD For High Risk SMM (PRISM)


- Jun 25, 2021
What are the different stages of Multiple Myeloma? REVISED - INTERNATIONAL STAGING SYSTEM (R-ISS)


- Jun 25, 2021
NCI National Cancer Institute: Manufacturing CAR T Cells to Accelerate Cancer Immunotherapy Research


- Jun 24, 2021
Multiple Myeloma Research Foundation - MMRF - Genomics


- Jun 24, 2021
NCT04751877: Phase 3 - Isa-Rd +/- Bortezomib Non Frail NTE Myeloma Elderly Patients IFM2020-05


- Jun 24, 2021
Patient Symposium - MCRT Webcast Myeloma Crowd Round Table, 05/08/2021, Dana-Farber Cancer Institute


- Jun 24, 2021
NCT04939844: Phase 2: REST - Replacing Steroids in the Transplant Ineligble (REST)


- Jun 23, 2021
NCT04843579: Phase 2: Selinexor in Combination With Clarithromycin, Pom & Dex RRMM - ClaSPd


- Jun 23, 2021
NCT04802356: Phase 2: Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma


- Jun 23, 2021
Multiple Myeloma Research Foundation - MMRF - Clinical Trials


- Jun 23, 2021
NCT04937777: EMN 23 - Study on the Management & Outcome of Systemic AL Amyloidosis in Europe


- Jun 23, 2021
What is the MMRF CureCloud®? Welcome to the MMRF CureCloud! Multiple Myeloma Research Foundation


- Jun 23, 2021
American Cancer Society - www.cancer.org: What is CART Cell Therapy?


- Jun 22, 2021
NCT04935580: Phase 1/2: Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients


- Jun 22, 2021
Patient Symposium - MCRT Webcast Myeloma Crowd Round Table, 04/24/2021